On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Drugmaker AbbVie Inc raised its full-year profit forecast on Friday, bolstered by signs of recovery in demand for its Botox injection on easing COVID-19 restrictions and strong growth for its latest ...
AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback